HAPPE Spine Announces Close Of $3.35 Million Round In Series A Investment

HAPPE Spine is an emerging leader in the development of next-generation orthopedic and spinal implants enabled by the HAPPE™ material platform. Today they announced that it has closed on a $3.35 million Series A capital raise. The oversubscribed funding was led by strategic investors from within the spine industry along with prominent and continuing investment by the Genesis Innovation Group’s cultivate(MD) Seed II Fund.

HAPPE’s orthopedic material platform, HydroxyApatite Porous PEek (HAPPE™), transforms polyetheretherketone (PEEK) from a hydrophobic, bioinert, and non-integrating material into a hydrophilic, bioactive, and osteointegrating material.  As such, the HAPPE™ material platform promises to improve clinical outcomes in spinal fusion by augmenting the radiolucency, bone-like mechanical properties, and subsidence resistance of conventional PEEK with designed cancellous porosity and bioactive surfaces for osteointegration.

Dr. Daniel Riew, MD, Professor of Orthopedics at Cornell and Columbia Universities, and a leading expert in cervical spine surgery said, “I look forward to utilizing HAPPE’s porous and bioactive PEEK, which has all the radiographic and clinical benefits of a synthetic cage while overcoming the negative aspects of an inert, hydrophobic PEEK device that cannot osteointegrate.”

Dr. Stephen Smith, MD, Neurosurgeon at the Beacon Health System and a co-inventor of the HAPPE technology added, “If you combine the best of allograft and PEEK, you get HAPPE (HydroxyApatite Porous PEek).  HAPPE is both spine- and surgeon-friendly.  It is biologically compatible, strong and radiographically informative.”

The HAPPE™ material platform was originally invented at the University of Notre Dame under the direction of Dr. Ryan K. Roeder, PhD, Professor at the University and Founder of HAPPE Spine.  The company has received three patents to date with additional patents pending. Dr. Roeder is a board member and Chief Technology Officer at HAPPE Spine.

Dr. Roeder stated, “I am humbled and honored by the strong response to our Series A capital raise, especially considering that we intentionally targeted spine industry leaders for the majority of this raise.  We received robust buy-in from those who best understand the market opportunity for our biomaterial platform.”

The company will apply the Series A funding proceeds to launch an innovative interbody spinal fusion implant, with a focus on completing final regulatory testing and obtaining 510k approval, as well as scaling manufacturing operations and the production of implant and instrument inventory. Several new strategic leadership and staff positions within the company will also be added.

Dr. Roeder added, “We are proud of the work our team has done to prepare for this next stage.  We have a versatile and innovative orthopaedic material platform that offers timely clinical solutions in interbody spinal fusion and additional opportunities for other orthopaedic applications we have in mind.  We have developed manufacturing operations that are cost-effective, scalable and adaptable for innovative implant designs.  We have assembled a preeminent clinical advisory board comprised of key opinion leaders from across the United States.  We are extremely excited to move ahead with our commercialization plans.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy